286
Participants
Start Date
August 1, 2012
Primary Completion Date
July 1, 2014
Study Completion Date
July 16, 2014
GSK2336805 40 mg
20 mg tablet, round, 10-mm diameter, white to off-white, no markings
GSK2336805 60 mg
30 mg tablet, round, 10-mm diameter, white to off-white, no markings
Pegylated interferon alpha-2a
180 microgram per 0.5 mL prefilled syringe for single use
Ribavirin
"200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side"
Telaprevir
375 mg film-coated tablet
GSK Investigational Site, Brussels
GSK Investigational Site, Sofia
GSK Investigational Site, Sofia
GSK Investigational Site, Sofia
GSK Investigational Site, Liège
GSK Investigational Site, Varna
GSK Investigational Site, New York
GSK Investigational Site, Berlin
GSK Investigational Site, Jenkintown
GSK Investigational Site, Hamburg
GSK Investigational Site, Baltimore
GSK Investigational Site, Annandale
GSK Investigational Site, Norfolk
GSK Investigational Site, Fayetteville
GSK Investigational Site, Asheville
GSK Investigational Site, Savannah
GSK Investigational Site, Columbus
GSK Investigational Site, DeLand
GSK Investigational Site, Orlando
GSK Investigational Site, Pessac
GSK Investigational Site, Dothan
GSK Investigational Site, Heidelberg
GSK Investigational Site, Lyon
GSK Investigational Site, Paris
GSK Investigational Site, Houston
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Las Vegas
GSK Investigational Site, Los Angeles
GSK Investigational Site, Anaheim
GSK Investigational Site, Würzburg
GSK Investigational Site, Brockton
GSK Investigational Site, Springfield
GSK Investigational Site, Ponce
GSK Investigational Site, San Juan
Lead Sponsor
Collaborators (1)
PPD Development, LP
INDUSTRY
GlaxoSmithKline
INDUSTRY